CD274 and neoplasm: As shown in Figure 10C–G, siPFKFB4/PRLPTX@RBCM‐cRGD, and PD‐L1 antibodies each achieved certain antitumor effects as monotherapies; however, their combination significantly enhanced tumor suppression.